Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.